Hong Kong Exchanges and Clearing

Hong Kong Exchanges and Clearing

Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as

to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon

the whole or any part of the contents of this notice.

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Incorporated in the Cayman Islands

with limited liability)

NOTICE OF ANNUAL GENERAL MEETING

HEREBY GIVEN THAT the AGM of Ascentage Pharma Group International (the "Company") will be held at 68 Xinqing Road,

Suzhou Industrial Park, Suzhou, Jiangsu, China on May 20, 2026 at 10:00 a.m. to transact the following business. In this notice, unless

the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company

(the "Circular") dated April 28, 2026.

ORDINARY RESOLUTIONS

shall not exceed 20% of the total

number of Shares in issue (excluding Treasury Shares, if any) as at the date of the passing of this resolution (subject to adjustment

in the case of any consolidation or subdivision of shares of the Company after the date of the passing of this resolution), and the said

mandate shall be limited accordingly; and

means the period from the passing of this resolution until whichever is the earliest of:

means an offer of shares open for a period fixed by the Directors to holders of Shares or any class of Shares whose names appear on the

register of members of the Company on a fixed record date in proportion to their then holdings of such Shares as at that date (subject

to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having

regard to any restrictions or obligations under the laws of, or the requirements of any recognized regulatory body or any stock exchange

in, any territory applicable to the Company)."

means the period from the passing of this resolution until whichever is the earliest of:

upon the passing of the resolutions set out in items 5 and 6 of the notice convening this meeting (the "Notice"), the

unconditional general mandate granted to the Directors to allot, issue and deal with additional shares and to make or grant offers, agreements,

and options which might require the exercise of such power pursuant to the resolution set out in item 5 of the Notice be and is hereby

extended by the addition thereto of an amount representing the aggregate number of Shares repurchased by the Company under the mandate

granted pursuant to the resolution set out in item 6 of the Notice, provided that such amount shall not exceed 10% of the total number

of Shares in issue (excluding Treasury Shares, if any) as at the date of the passing of this resolution (subject to adjustment in the

case of any consolidation or subdivision of shares of the Company after the date of the passing of this resolution)."

By Order of the Board

Ascentage Pharma Group International

Chairman and Executive Director

Suzhou, The People's Republic of China, April 28, 2026

date of this notice, the Board of Directors of the Company comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng

and Dr. Lu Simon DazhongNote1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David SidranskyNote2,

Ms. Marina S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.